Stanford

# Hiroyuki Shimada

Professor of Pathology and of Pediatrics at the Stanford University Medical Center

### CLINICAL OFFICES


- **Department of Pathology**

  300 Pasteur Dr

  Stanford, CA 94305

  **Tel** (650) 723-7211 **Fax** (650) 725-7409


## Bio

### BIO

Hiroyuki Shimada, MD, PhD, FRCPA (Hon), is Professor of Pathology and of Pediatrics at the Stanford University Medical Center. He was born in Tokyo, Japan, and completed MD (1973) and PhD (1982) at the Yokohama City University School of Medicine, Yokohama, Japan, and also completed his pathology training at the Children's Hospital (now the Nationwide Children's Hospital) and the Ohio State University, Columbus, Ohio, USA (1988). Before moving to the Stanford University in 2019, he was Professor of Pathology (Clinical Scholar) at the University of Southern California Keck School of Medicine and working at the Children's Hospital Los Angeles.

Dr. Shimada was Chair of the International Neuroblastoma Pathology Committee (1999-2017) and the founder of the International Neuroblastoma Pathology Classification (INPC). As Director of the COG (Children's Oncology Group) Neuroblastoma Pathology Reference Laboratory (since 2001), he has been actively reviewing pathology samples of ~700 neuroblastoma cases per year from United States, Canada, Australia, and New Zealand. Pathology review results according to the INPC have been providing critical information for patient stratification and protocol assignment in the COG international neuroblastoma clinical trials.

### CLINICAL FOCUS

- Pathology
- neuroblastoma

### ACADEMIC APPOINTMENTS

- Professor - Med Center Line, Pathology
- Professor - Med Center Line, Pediatrics
- Member, Maternal & Child Health Research Institute (MCHRI)

### HONORS AND AWARDS

- Enid Gilbert-Barness Prize, Society for Pediatric Pathology (2018)
- Honorary Fellowship, Royal College of Pathologists of Australasia (2012)
- Eleanor Humpherys Visiting Professorship, University of Chicago (2005)
- Lotte Straus Prize, Society for Pediatric Pathology (1989)

### PROFESSIONAL EDUCATION

- Residency: Nationwide Children's Hospital Pediatric Pathology (1988) OH
- Board Certification: Pathology, Japanese Society of Pathology (1981)

- Medical Education: Yokohama City University School of Medicine (1973) Japan

## Publications

### PUBLICATIONS

- **Enhancing sustained-release local therapy: Single versus dual chemotherapy for the treatment of neuroblastoma.** *Surgery*
  Taylor, J. S., Yavuz, B., Zeki, J., Wood, L., Ikegaki, N., Coburn, J., Harrington, K., Shimada, H., Kaplan, D. L., Chiu, B.
  2020

- **Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model.** *Cancer medicine*
  Ornell, K. J., Taylor, J. S., Zeki, J., Ikegaki, N., Shimada, H., Coburn, J. M., Chiu, B.
  2020

- **MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma.** *Cell death & disease*
  Wei, S. J., Nguyen, T. H., Yang, I. H., Mook, D. G., Makena, M. R., Verlekar, D., Hindle, A., Martinez, G. M., Yang, S., Shimada, H., Reynolds, C. P., Kang, M. H.
  2020; 11 (5): 368

- **Pathology of Peripheral Neuroblastic Tumors: An Update**
  Shimada, H.
  WILEY.2019: S1–S2

- **Optimizing Sustained Release Local Therapy: Single vs Dual Chemotherapy for the Treatment of Neuroblastoma**
  Taylor, J. S., Yavuz, B., Zeki, J., Ikegaki, N., Coburn, J. M., Harrington, K., Shimada, H., Kaplan, D. L., Chiu, B.
  ELSEVIER SCIENCE INC.2019: S210–S211

- **Replicating and identifying large cell neuroblastoma using high-dose intra-tumoral chemotherapy and automated digital analysis.** *Journal of pediatric surgery*
  Taylor, J. S., Sha, L., Ikegaki, N., Zeki, J., Deaton, R., Harris, J., Coburn, J., Yavuz, B., Sethi, A., Shimada, H., Kaplan, D. L., Gann, P., Chiu, et al
  2019

- **Down-regulation of MYCN protein by CX-5461 leads to neuroblastoma tumor growth suppression**
  Taylor, J. S., Zeki, J., Ornell, K., Coburn, J., Shimada, H., Ikegaki, N., Chiu, B.
  W B SAUNDERS CO-ELSEVIER INC.2019: 1192–97

- **Down-regulation of MYCN protein by CX-5461 leads to neuroblastoma tumor growth suppression.** *Journal of pediatric surgery*
  Taylor, J. S., Zeki, J., Ornell, K., Coburn, J., Shimada, H., Ikegaki, N., Chiu, B.
  2019

- **Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
  Wu, H. W., Sheard, M. A., Malvar, J., Fernandez, G. E., DeClerck, Y. A., Blavier, L., Shimada, H., Theuer, C. P., Sposto, R., Seeger, R. C.
  2019; 25 (15): 4761–74

- **MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group.** *Oncotarget*
  Niemas-Teshiba, R., Matsuno, R., Wang, L. L., Tang, X. X., Chiu, B., Zeki, J., Coburn, J., Ornell, K., Naranjo, A., Van Ryn, C., London, W. B., Hogarty, M. D., Gastier-Foster, et al
  2018; 9 (5): 6416–32

- **Dose Escalation Study of No-Carrier-Added I-131-Metaiodobenzylguanidine for Relapsed or Refractory Neuroblastoma: New Approaches to Neuroblastoma Therapy Consortium Trial** *JOURNAL OF NUCLEAR MEDICINE*
  Matthay, K. K., Weiss, B., Villablanca, J. G., Maris, J. M., Yanik, G. A., DuBois, S. G., Stubbs, J., Groshen, S., Tsao-Wei, D., Hawkins, R., Jackson, H., Goodarzian, F., Daldrup-Link, et al
  2012; 53 (7): 1155-1163

- **Outcome analysis of non-high-risk neuroblastoma patients enrolled on Children's Oncology Group trials P9641 and A3961**
  Meany, H., Attiyeh, E. F., Naranjo, A., Twist, C., London, W. B., Villablanca, J., Schmidt, M., Baker, D., Strother, D. R., Shimada, H., Matthay, K. K., Cohn, S., Maris, et al

AMER SOC CLINICAL ONCOLOGY.2012

- **Current Treatment Protocols Have Eliminated the Prognostic Advantage of Type 1 Fusions in Ewing Sarcoma: A Report From the Children's Oncology Group** *JOURNAL OF CLINICAL ONCOLOGY*

  van Doorninck, J. A., Ji, L., Schaub, B., Shimada, H., Wing, M. R., Krailo, M. D., Lessnick, S. L., Marina, N., Triche, T. J., Sposto, R., Womer, R. B., Lawlor, E. R.

  2010; 28 (12): 1989-1994

- **Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations** *CANCER RESEARCH*

  Ren, Y., Finckenstein, F., Abdueva, D. A., Shahbazian, V., Chung, B., Weinberg, K. I., Triche, T. J., Shimada, H., Anderson, M. J.

  2008; 68 (16): 6587–97

- **Primary and metastatic rhabdomyosarcoma in the breast: Neoplasms of adolescent females, a report from the intergroup rhabdomyosarcoma study** *MEDICAL AND PEDIATRIC ONCOLOGY*

  Hays, D. M., Donaldson, S. S., Shimada, H., Crist, W. M., Newton, W. A., Andrassy, R. J., Wiener, E., Green, J., Triche, T., Maurer, H. M.

  1997; 29 (3): 181-189